June 1, 2021 Lab Top-10 Mass Spectrometry Product Launch

Bruker Launches timsTOF SCP for Unbiased Single Cell 4D-Proteomics and Next-gen timsTOF Pro 2 with Unprecedented Proteomic Depth

Unique timsTOF SCP revolutionizes quantitative single cell biology research with unbiased, deep single-cell 4D-Proteomics™ to complement scRNA-seq; breakthrough paper by Mann et al. identifies and quantifies >1,400 proteins in single cells Next-generation timsTOF Pro 2 with unprecedented depth and throughput for unbiased 4D-Proteomics; supports liquid biopsy multiomic biomarker research, integrating genomics with proteomics and epiproteomics;... Read more

June 1, 2021 Lab Top-10 Mass Spectrometry Product Launch

Bruker Launches timsTOF trueSCP for Unbiased Single Cell 4D-Proteomics and Next-gen timsTOF Pro 2 with Unprecedented Proteomic Depth

Unique timsTOF trueSCP revolutionizes quantitative single cell biology research with unbiased, deep single-cell 4D-Proteomics™ to complement scRNA-seq; breakthrough paper by Mann et al. identifies and quantifies >1,400 proteins in single cells Next-generation timsTOF Pro 2 with unprecedented depth and throughput for unbiased 4D-Proteomics; supports liquid biopsy multiomic biomarker research, integrating genomics with proteomics and epiproteomics;... Read more

May 25, 2021 PAI Top-10 Product Launch

European Commission approves Venclyxto-based combinations for adults with newly diagnosed acute myeloid leukaemia who are ineligible for intensive chemotherapy

With hypomethylating agents significantly improved complete response rates in certain adults with newly diagnosed acute myeloid leukaemia In the VIALE-A study, Venclyxto plus azacitidine significantly improved overall survival in patients ineligible for intensive chemotherapy, a patient population who typically have a five-year overall survival rate of less than 10%1 Study data reinforces the potential of... Read more

May 21, 2021 PR/Corporate Product Launch

Pacific Biosciences Grants Equity Incentive Award to New Employee

MENLO PARK, Calif., May 21, 2021 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequencing of genomes, transcriptomes, and epigenomes, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 240,000 shares of... Read more

May 20, 2021 Atomic Spectroscopy Environ, Ag./Food & Bev Lab Top-10 Product Launch

Bruker’s Molecular Phenomics Research Tools Enable New Insights into ‘Long COVID’ and Post-Acute Metabolic Abnormalities

Australian National Phenome Centre Integrates Quantitative NMR and MS Assay Platform for Risk Assessment and Longitudinal Monitoring of Post-Acute COVID-19 Syndrome (PACS) PERTH, Australia–(BUSINESS WIRE)– A clinical research collaboration on COVID-19 pheno-conversion and subsequent pheno-reversion has discovered transient and persistent systemic changes of the molecular signatures in patient blood samples three months after the acute... Read more

May 13, 2021 Lab Top-10 Product Launch

Bruker Announces New Two-Year Share Repurchase Authorization of up to $500 Million; Board also Declares Quarterly Dividend

BILLERICA, Mass.–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR) today announced that on May 12, 2021, its Board of Directors approved a new share repurchase authorization for the purchase of up to $500 million of the Company’s common stock over a two-year period commencing on May 13, 2021. The share repurchase authorization permits shares to be repurchased... Read more

May 11, 2021 Clinical Research/Diagn. PAI Top-10 Product Launch

Roche to present data from one of the most comprehensive oncology portfolios at the 2021 ASCO Annual Meeting showcasing advancements for people living with cancer

Data from the first positive phase III study of a cancer immunotherapy in early, resected lung cancer Studies in personalised healthcare exploring tumour agnostic treatments that demonstrate the impact of coupling biomarker testing with targeted therapies to develop individualised treatment plans New data, and drug combination strategies for the treatment of lymphoma from the largest... Read more

May 10, 2021 Product Launch

GE Healthcare Introduces a New Virtual Solution with AI Enabled Applications For Precision Health in Nuclear Medicine

CHICAGO, 10 May 2021 – To help provide nuclear medicine clinicians greater flexibility and more time with patients, GE Healthcare today unveiled Xeleris V – a new virtual processing and review solution. Xeleris V eliminates the need for a standalone nuclear medicine workstation so that clinicians can have secure access to data from various locations.... Read more